Jenburkt Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for September 4, 2026, at 3:30 p.m. IST. The meeting will be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI-LODR). Shareholders holding shares as of the August 28, 2026 cut-off date are eligible to vote on all resolutions presented in the notice.

The company dispatched the notice convening the AGM, along with the Annual Report for the financial year 2025-26 (FY25-26), to members via electronic mode on August 3, 2026. This dispatch was made in accordance with Rule 20(4) of the Companies (Management and Administration) Rules, 2014, and Ministry of Corporate Affairs General Circular No. 03/2025 dated September 22, 2025. Newspaper advertisements confirming the meeting were published in The Free Press Journal (English) and Navshakti (Marathi) on August 4, 2026.

E-Voting Schedule and Eligibility

Members can cast their votes using the remote e-voting facility provided by National Securities Depository Limited (NSDL). The voting window is open for three days prior to the AGM. Voting rights are proportional to the paid-up value of equity shares held as of the cut-off date.

Once a vote is cast via remote e-voting, it cannot be changed. Members who have already voted remotely may attend the AGM via VC/OAVM but cannot vote again. Those attending the meeting who have not voted remotely may exercise their voting rights during the AGM or within 15 minutes after its conclusion.

Regulatory Compliance and Member Instructions

The company complied with Regulation 36(1)(b) of SEBI-LODR by sending letters containing web-links to the complete Annual Report details to members who have not registered their email addresses with the company, Registrar to an Issue & Share Transfer Agent (RTA), or Depository Participants (DPs). The full notice and annual report are available on the company’s website at www.jenburkt.com and the BSE Limited website at www.bseindia.com .

Members are advised to update their PAN, contact details, bank account information, specimen signatures, and nomination details with their DPs if shares are held in demat form. Physical shareholders must submit duly filled Forms ISR-1 and ISR-2 to the company or RTA. Service requests can also be submitted online via the RTA’s ‘iConnect’ portal. For queries regarding login IDs or e-voting, members may contact NSDL’s Assistant Vice President, Veena Suvarna, or refer to the FAQs on www.evoting.nsdl.com .

Jenburkt Pharmaceuticals Limited reported an 8.34% year-on-year increase in net profit after tax (PAT) to ₹3,473.60 lacs for the financial year ended March 31, 2026 (FY26), driven by robust top-line growth and operational efficiencies. Revenue from operations rose 13.02% to ₹16,874.06 lacs, reflecting strong demand across its pharmaceutical portfolio. The Board of Directors recommended a final dividend of ₹20.70 per equity share, representing a 207% payout on the ₹10 face value, signaling confidence in the company’s cash generation capabilities. Shareholders will vote on this dividend and other key agenda items at the 41st Annual General Meeting (AGM) scheduled for September 4, 2026.

The results were filed with the Bombay Stock Exchange under Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM will also see shareholders vote on the reappointment of Dilip H. Bhuta as Whole Time Director and Chief Financial Officer for five years, alongside ratifying the remuneration of cost auditor M/s. Kirit Mehta & Co. LLP at ₹2,75,000 plus taxes for FY27. Statutory auditors D. R. Mehta & Associates issued an unmodified opinion on the financial statements.

Financial Performance Overview

The company’s total income reached ₹17,904.00 lacs, up from ₹15,841.25 lacs in FY25. Profit before tax increased 14.88% to ₹4,651.89 lacs, although this figure includes exceptional items related to revised labor codes. Earnings per share (EPS) grew to ₹78.71 from ₹72.65 in the previous year. Reserves and surplus expanded by 15.09% to ₹19,262.69 lacs, reinforcing balance sheet strength. The company remains debt-free and cash-rich, with a current ratio improving to 4.11 times from 3.00 times in the prior year.

What the Numbers Show

A significant divergence exists between pre-tax profit growth and net profit growth due to exceptional items. The company recorded ₹395.11 lacs in exceptional expenses arising from past service costs linked to the implementation of new labor codes notified in November 2025. Without this one-time charge, underlying profitability would have been substantially higher. Additionally, other income surged to ₹1,029.94 lacs from ₹672.10 lacs, contributing materially to total income through interest earnings and foreign exchange gains. Foreign exchange earnings specifically reached ₹2,612.01 lacs, up from ₹1,904.79 lacs in FY25.

Governance and Corporate Actions

Shareholders will decide on the reappointment of Dilip H. Bhuta, who has served since July 2013. His proposed remuneration is capped at ₹108.00 lacs per annum for three years starting April 2027. The company also highlighted its CSR initiatives, spending ₹65.00 lacs on healthcare projects, including the 'Asha Van' for cancer screening in rural Gujarat. Secretarial auditor Nilesh Shah & Associates confirmed compliance with corporate governance norms.